No abstract

PGE(2) is a potent in vivo suppressor of NK activity, and its postoperative release may promote tumor recurrence.

How do we identify people? What are the critical facial features that define an identity and determine whether two faces belong to the same person or different people? To answer these questions, we applied the face space framework, according to which faces are represented as points in a multidimensional feature space, such that face space distances are correlated with perceptual similarities between faces. In particular, we developed a novel method that allowed us to reveal the critical dimensions (i.e., critical features) of the face space. To that end, we constructed a concrete face space, which included 20 facial features of natural face images, and asked human observers to evaluate feature values (e.g., how thick are the lips). Next, we systematically and quantitatively changed facial features, and measured the perceptual effects of these manipulations. We found that critical features were those for which participants have high perceptual sensitivity (PS) for detecting differences across identities (e.g., which of two faces has thicker lips). Furthermore, these high PS features vary minimally across different views of the same identity, suggesting high PS features support face recognition across different images of the same face. The methods described here set an infrastructure for discovering the critical features of other face categories not studied here (e.g., Asians, familiar) as well as other aspects of face processing, such as attractiveness or trait inferences.

No abstract

MP-NK cells are unique in their ability to kill this apparently immunoresistant tumor. Low doses of synthetic ds-RNA (poly I-C), and potentially Th1 cytokines, can expand this MP-NK population and protect it from immunosuppression. The novelty of such a prophylactic approach is targeting the immediate postoperative period, which is characterized by high vulnerability to residual disease, and protecting critical anti-metastatic immunity against postoperative suppression. Testing such a potentially innocuous intervention in oncology patients preparing for surgery may reduce metastatic recurrence.